ClpP 是一种高度保守的丝氨酸蛋白酶，在维持细菌细胞和人类线粒体中的蛋白质稳态中发挥着至关重要的作用。多项研究表明 ClpP 作为药物靶点的潜力，其中 ClpP 调节剂（包括抑制剂和激活剂）在治疗耐药细菌、恶性肿瘤和脂肪肝等一系列疾病方面显示出前景。过去五年提交的 ClpP 调节剂相关专利概述，详细说明其权利要求和治疗应用。专利信息来源包括欧洲专利局、中国专利局和美国专利局的数据库，相关研究文章通过PubMed获取。ClpP调节剂的专利数量呈上升趋势，反映了相关研究的进展。通过总结和概述相关专利，我们旨在激发研究人员的进一步兴趣，最终开发出基于 ClpP 调节剂的有效药物。与 ClpP 功能障碍相关的广泛疾病强调了 ClpP 调节剂满足广泛治疗需求的潜力。

ClpP is a highly conserved serine protease that plays a crucial role in maintaining protein homeostasis in both bacterial cells and human mitochondria. Several studies have demonstrated the potential of ClpP as a drug target, with ClpP modulators, including both inhibitors and activators, showing promise in treating a range of conditions such as drug-resistant bacteria, malignant cancers, and fatty liver disease.This review provides an overview of patents related to ClpP modulators filed over the last five years, detailing their claims and therapeutic applications. The sources of patent information included databases of the European Patent Office, the China Patent Office and the U.S.A. patent Office, while relevant research articles were accessed through PubMed.The number of patents concerning ClpP modulators is on the rise, reflecting advancements in related research. By summarizing and outlining relevant patents, we aim to stimulate further interest among researchers, ultimately leading to the development of effective drugs based on ClpP modulators. The broad spectrum of diseases associated with ClpP dysfunction underscores the potential for ClpP modulators to address a wide range of therapeutic needs.